One stop solution for genetic classification of Multiple Myeloma

Next-generation sequencing (NGS) has played a crucial role in advancing our understanding of various disease, including cancer.

For Patients
For Clinicians

Introduction to PlasmaSEQ 

& it’s role in Myeloma diagnostics

Next-generation sequencing (NGS) has played a crucial role in advancing our understanding of various diseases, including cancer. In the context of Multiple Myeloma (MM), NGS has been employed to unravel the genomic landscape, identify key genetic mutations, but till now has failed to make it to the routine clinical care across the globe.

Know More

Introduction to PlasmaSEQ 

& it’s role in Myeloma diagnostics

Next-generation sequencing (NGS) has played a crucial role in advancing our understanding of various diseases, including cancer. In the context of Multiple Myeloma (MM), NGS has been employed to unravel the genomic landscape, identify key genetic mutations, but till now has failed to make it to the routine clinical care across the globe.

Know More

Difference between

PlasmaSEQ vs FISH

PlasmaSEQ

Del (17p)

Del (1p32)

1q21 amplification/gain

IGH Translocations

t(4;14)IGH::FGFR3

t(14;16)IGH::MAF

t(11;14)IGH::CCND1

t(6;14)IGH::CCND3

t(14;20)IGH::MAFB

TP53 Mutation

BRAF V600E

All RAS/RAF Mutations

DIS3-DEL(13q) Mutation

SLAMF7, BCMA & APRIL* and GPRC5D

Genomic Profiling of ATM

Trisomies & Hyperdiploidy 
across the genome

FISH

Del (17p)

Del (1p32)

1q21 amplification/gain

IGH Translocations

t(4;14)IGH::FGFR3

t(14;16)IGH::MAF

t(11;14)IGH::CCND1

t(6;14)IGH::CCND3

t(14;20)IGH::MAFB

*To be released in upcoming Plasmaseq 2.0

Why PlasmaSEQ

  • 1st Global NGS based test for Myeloma.
  • Validated for DNA input per sample of as low as 10 ng.
  • >1000 Samples validated in 3 countries with >95% accuracy.
  • Rapid turn around time
  • One stop test for detecting all genomic events including biallelic somatic changes
Know More

Feature

Eliminates the need of multiple assays like FISH and karyotyping

Able to pick up mutations including TP53 and other which are not checked by FISH

Advantage

Sample is not a limiting factor unlike in FISH where search for IGH partner can result into depletion of sample

Benefits

Cover CNVs across the genome relevant to Myeloma; hence, trisomies in all relevant chromosomes can be detected which is not routinely checked by FISH

FAQ's

Minimum sample: 2 ml of EDTA-Bone Marrow
PlasmaSEQ is a comprehensive, all-in-one solution for Multiple Myeloma cases. This next-generation sequencing (NGS) method offers an extensive genomic overview, covering IGH translocations, mutations, amplifications, Trisomies & Hyperdiploidies. It eliminates the need for multiple assays such as karyotyping and FISH, while providing in-depth insights.
PlasmaSEQ checks Bi-allelic deletions (CDKN2C), multi-exonic (TP53) deletions that are missed by FISH and helps determine the course of targeted therapy (Immunotherapy).
PlasmaSEQ can perform testing with as little as 1 nanogram per μL of DNA, ensuring that physicians obtain the maximum amount of information from low sample volume.

Connect with us to get more information about PlasmaSEQ

Contact Us